Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Glycoprofiling test could halve number of false-positives in diagnosis of ovarian cancer

11 Mar 2014

Scientists discover new protein that drive metastasis of cancer cells

An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body.

11 Mar 2014

New sugar-test may reduce false-positive ovarian cancer screening tests

The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

10 Mar 2014

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Tekmira Pharmaceuticals and the Vanderbilt University Medical Center have been awarded up to $26 million to advance treatments of the highly lethal hemorrhagic fever viruses Ebola and Marburg.

6 Mar 2014

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

6 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

5 Mar 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2013.

28 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

Infliximab drug shows promising results in treating children with Kawasaki Disease

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. If not diagnosed or treated in time, it can lead to irreversible heart damage.

25 Feb 2014

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

19 Feb 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

31 Jan 2014

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers have discovered a potential treatment for a viral infection that causes potentially fatal brain swelling and paralysis in children. The findings also point to possible treatments for related viruses including those that cause "common cold" symptoms.

29 Jan 2014

Monoclonal Antibody News and Research

Further Reading

Glycoprofiling test could halve number of false-positives in diagnosis of ovarian cancer

Scientists discover new protein that drive metastasis of cancer cells

New sugar-test may reduce false-positive ovarian cancer screening tests

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

Important facts about colorectal cancer

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Infliximab drug shows promising results in treating children with Kawasaki Disease

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

Novartis acquires CoStim Pharmaceuticals

Alvogen launches Inflectra into Central and Eastern Europe

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Llama-derived antibodies open door to development of new treatments for C. difficile infections

Researchers discover potential treatment for viral infection that causes illnesses in children

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®